학술논문

Febrile infection-related epilepsy syndrome (FIRES): prevalence, impact and management strategies
Document Type
Academic Journal
Source
Neuropsychiatric Disease and Treatment. July, 2019, p1897, 7 p.
Subject
Company business management
Strategic planning (Business) -- Health aspects
Intravenous immunoglobulins -- Health aspects
Epilepsy -- Care and treatment -- Development and progression -- Health aspects
Drug resistance -- Care and treatment -- Development and progression -- Health aspects
Seizures (Medicine) -- Care and treatment -- Development and progression -- Health aspects
Epidemiology -- Health aspects
Encephalitis -- Care and treatment -- Development and progression -- Health aspects
Etiology (Medicine)
Biological markers
Encephalopathy
Infection
Status epilepticus
Terms and phrases
Language
English
ISSN
1176-6328
Abstract
Febrile infection-related epilepsy syndrome (FIRES) is a rare catastrophic epileptic encephalopathy with a yet undefined etiology, affecting healthy children. It is characterized by acute manifestation of recurrent seizures or refractory status epilepticus preceded by febrile illness, but without evidence of infectious encephalitis. To date, the absence of specific biomarkers poses a significant diagnostic challenge; nonetheless, early diagnosis is very important for optimal management. FIRES is mostly irreversible and its sequelae include drug-resistant epilepsy and neuropsychological impairments. The treatment of FIRES represents a significant challenge for clinicians and is associated with low success rates. Early introduction of ketogenic diet seems to represent the most effective and promising treatment. This review aims to highlight the most recent insights on clinical features, terminology, epidemiology, pathogenesis, diagnostic challenges and therapeutic options. Keywords: FIRES, NORSE, epilepsy syndromes, inflammatory epilepsies, status epilepticus, drug-resistance
Introduction The acronym FIRES stands for "Febrile Infection Related Epilepsy Syndrome" and was used for the first time by van Baalen and colleagues in 2010, (1) although the same clinical [...]